Citations

Clear

400 citation(s) found for "Berry, DA".

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Daly, Mary B., Dickson, Patricia , Elkhanany, Ahmed , Friedman, Susan , Hutton, Mollie L., CGC, Khan, Seema, Klein, Catherine, Kohlmann, Wendy , CGC, Kurian, Allison W. , Laronga, Christine , Mak, Julie , LCGC, Menendez, Carolyn S. , Merajver, Sofía D. , Norquist, Barbara S., Offit, Kenneth , Pederson, Holly J. , Reiser, Gwen , CGC, Senter-Jamieson, Leigha, CGC, Shannon, Kristen M. , Shatsky, Rebecca , Visvanathan, Kala , Weitzel, Jeffrey N. , Wick, Myra , Wisinski, Kari B. , Yurgelun, Matthew B. , Darlow, Susan, Dwyer, Mary A., Norquist, Barbara M. , Weitzel, Jeffrey N , Visvanathan, Kala , Kurian, Allison W , Norquist, Barbara , Elkhanany, Ahmed , Shatsky, Rebecca , Pal, Tuya , Berry, Michael P., Buys, Saundra S. , Domchek, Susan M. , Goggins, Michael , CGC, Karlan, Beth Y. , CGC, Litton, Jennifer K. , LCGC, CGC, CGC

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 6, 2021 | Volume: 19 | Issue: 1 | Pages: 77-102

10.6004/jnccn.2021.0001 | PMID 33406487 Get It

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies in individuals with these pathogenic or likely pathogenic variants. This manuscript focuses on cancer risk and risk management for BRCA-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies. There is also evidence that risks of prostate cancer and pancreatic cancer are elevated in these carriers. Li-Fraumeni syndrome is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors.
Completeness of Social and Behavioral Determinants of Health in Electronic Health Records: A case study on the Patient-Provided Information from a minority cohort with sexually transmitted diseases
Kshatriya, Bhavani Singh Agnikula , Zhang, Rui , Wang, Yanshan , Wang, Yanshan , Balls‐Berry, Joyce E. , Freeman, William D.

Mayo Clinic

No container title available | December 10, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-123744/v1 Get It

Abstract IntroductionRacially and ethnically diverse minorities often experience the disease burden of sexually transmitted infections or diseases (STD) more often than their White counterparts. Yet, little is known about the connection of STD systematic discrimination, racism, and social and behavioral determinants. Plus, little to no details exists related to how this information is recorded in their Electronic Health Records (EHRs). The objective of this study is to assess the completeness of social and behavioral determinants of health (SDOH) data in the EHRs of a minority cohort with STD.Materials and Methods2,993 minority patients diagnosed with a STD at the Mayo Clinic were identified for this study. A natural language processing (NLP) algorithm was applied on the Patient-Provided Information (PPI) in their EHRs to extract SDOH information in six domains that are associated with STD, namely alcohol use, substance use, sexual activity, sexual orientation, housing status, and employment status. The completeness of SDOH was assessed in terms of documentation, breadth, and density.ResultsOur study indicates that nearly half of 2,993 patients did not have SDOH-related PPI records in their EHRs whereas the patients who had SDOH-related PPI records had well-documented records for five out of six SDOH domains, including alcohol use, substance use, sexual activity, housing status, and employment status, except for sexual orientation. A total of 1,504 patients had PPI in their EHRs for at least one of six SDOH domains, which is about 50.3% of the study cohort. Most SDOH domains have a short time span of 1 year, with up to 18 years of record data. Our analysis also indicated that education and age have a significant impact on the recording of SDOH-related PPI records. Patients that are female, older, and higher educated tend to have more SDOH information available in their records.Discussion and ConclusionWe assessed the completeness of SDOH information recorded in the PPI from patients’ EHRs. Due to large amounts of missing SDOH information in the PPI, future research is needed to integrate accurate and robust SDOH related data for downstream research and the impact of systematic discrimination on how this information is collected and interpreted in the EHRs.
Latent disease models estimate symptom onset in familial frontotemporal lobar degeneration and enable novel designs for early‐stage clinical trials
Staffaroni, Adam M. , Quintana, Melanie , Wendelberger, Barbara , Heuer, Hilary W. , Goh, Sheng‐Yang Matthew, Wolf, Amy, Onyike, Chiadi U. , Rosen, Howard J. , Boxer, Adam L. , Wendelberger, Barbara , Rojas, Julio C. , Cobigo, Yann , Wolf, Amy, Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.045854 Get It

AbstractBackgroundMeasuring changes in the earliest phases of familial frontotemporal lobar degeneration (f‐FTLD) and estimating symptom onset has important implications for clinical care. Early stage clinical trials have begun for f‐FTD, but the low prevalence of f‐FTLD mutation carriers and heterogeneous symptomology challenges trial design. Bayesian disease progression models (DPM) incorporate clinical data, neuroimaging metrics, and fluid biomarker concentrations to estimate latent disease age, providing estimates of symptom onset and progression status. Such models may facilitate enrollment in studies (i.e., inclusion of presymptomatic individuals) and provide more powerful analysis methods for trials.MethodA Bayesian latent variable repeated measures model was used to estimate disease progression, conditional on latent disease age (proximity to symptom onset), in 275 participants with mutations in GRN (n=68), MAPT (n=80) and C9orf72 (n=127). Median follow‐up was one year (range: 0‐4). Jointly modeled longitudinal variables included neuropsychological scores, CDR®+NACC‐FTLD box score, 3T MRI frontotemporal brain volumes, and plasma levels of neurofilament light chain (NfL). Sample size estimates for detecting treatment effects were generated by varying thresholds of estimated proximity to symptom onset.ResultThe Bayesian DPM provided a clear picture of clinical and neurological progression within each mutation group. Neuroimaging and NfL captured early progression rates (1 SD from controls) 5‐10 years before symptom onset. After symptom onset, CDR®+NACC‐FTLD box score was the most sensitive measure of disease progression. GRN mutation carriers had the largest annual progression rates (and lowest variability) compared to MAPT and C9orf72. Between 5 years pre‐ and 10 years post‐onset, CDR®+NACC‐FTLD box score progressed by 2 units/year (SD=2.7) in GRN mutation carriers ‐ almost twice the rate of progression in MAPT (M=1.2;SD=2.5) and C9orf72 (M=1.1;SD=2.2) mutation carriers. Compared to a trial enrolling only early symptomatic cases (CDR®+NACC‐FTLD=0.5 or 1), utilizing latent disease age would facilitate enrollment of asymptomatic cases with the same power.ConclusionBased on an estimation of symptom onset, Bayesian DPMs suggest clinical trials in GRN mutation carriers would require the smallest sample sizes. Furthermore, leveraging these DPMs would allow novel, powerful trial designs that may facilitate greater participant enrollment.
Direct Inpatient Medical Costs of Operative Treatment of Periprosthetic Hip and Knee Infections Are Twofold Higher Than Those of Aseptic Revisions
Yao, Jie , Hevesi, Mario , Visscher, Sue L. , Ransom, Jeanine E. , Lewallen, David G. , Berry, Daniel J. , Kremers, Hilal Maradit , Yao, Jie J , Maradit Kremers, Hilal, Maradit Kremers, Hilal , Berry, Daniel J , Hevesi, Mario

Mayo Clinic

Journal of Bone and Joint Surgery | December 2, 2020 | Volume: 103 | Issue: 4 | Pages: 312-318

10.2106/jbjs.20.00550 | PMID 33252589 Get It

Background: Periprosthetic joint infections (PJIs) following total hip arthroplasty (THA) and total knee arthroplasty (TKA) are associated with substantial morbidity. A better understanding of the costs of PJI treatment can inform prevention, treatment, and reimbursement strategies. The purpose of the present study was to describe direct inpatient medical costs associated with the treatment of hip and knee PJI. Methods: At a single tertiary care institution, 176 hips and 266 knees that underwent 2-stage revisions for the treatment of PJI from 2009 to 2015 were compared with 1,611 hips and 1,276 knees that underwent revisions for aseptic indications. In addition, 84 hips and 137 knees that underwent irrigation and debridement (I&D) with partial component exchange were compared with 39 hips and 138 knees that underwent partial component exchange for aseptic indications. Line-item details of services billed during hospitalization were retrieved, and standardized direct medical costs were calculated in 2018 inflation-adjusted dollars. Results: The mean direct medical cost of 2-stage revision THA performed for the treatment of PJI was significantly higher than that of aseptic revision THA ($58,369 compared with $22,846, p < 0.001). Similarly, the cost of 2-stage revision TKA performed for the treatment of PJI was significantly higher than that of aseptic revision TKA ($56,900 compared with $24,630, p < 0.001). Even when the total costs of aseptic revisions were doubled for a representative comparison with 2-stage procedures, the costs of PJI procedures were 15% to 28% higher than those of the doubled costs of aseptic revisions (p < 0.001). The mean direct medical cost of I&D procedures for PJI was about twofold higher than of partial component exchange for aseptic indications. Conclusions: The direct medical costs of operative treatment of PJI following THA and TKA are twofold higher than the costs of similar aseptic revisions. The high economic burden of PJI warrants efforts to reduce the incidence of PJI. Reimbursement schemes should account for the high costs of treating PJI in order to ensure sustainable patient care. Level of Evidence: Economic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Extended Trochanteric Osteotomy in Revision Total Hip Arthroplasty
Abdel, Matthew P. , Wyles, Cody C. , Viste, Anthony , Perry, Kevin I. , Trousdale, Robert T. , Berry, Daniel J. , Abdel, Matthew P , Wyles, Cody C , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | December 2, 2020 | Volume: 103 | Issue: 2 | Pages: 162-173

10.2106/jbjs.20.00215 | PMID 33252587 Get It

Background: Extended trochanteric osteotomies (ETOs) provide wide femoral and acetabular exposure, give direct access to the femoral medullary canal, and facilitate implant removal and new implant placement during selected revision total hip arthroplasties (THAs). Previous studies are limited by modest patient numbers and limited length of follow-up. The goals of the current study were to assess the union rate, complications, and outcomes of contemporary ETOs performed during revision THAs. Methods: From 2003 to 2013, 612 ETOs were performed during revision THAs at 1 institution using 2 techniques: Paprosky (laterally based osteotomy; n = 367) and Wagner (anteriorly based osteotomy; n = 245). The indications for the revision procedures were aseptic loosening (65%), periprosthetic joint infection (18%), periprosthetic fracture (6%), femoral implant fracture (5%), and other (6%). The mean patient age was 69 years, and 57% of the patients were male. The mean number of previous THAs was 1.6. The median duration of follow-up was 5 years (range, 2 to 13 years). Results: The mean Harris hip scores increased from 57 preoperatively to 77 at the latest follow-up (p < 0.001). Radiographic and clinical union was achieved in 98% of the patients at a mean of 6 months (range, 1 to 24 months). The mean migration of the proximal trochanteric osteotomy fragment prior to union was 3 mm (range, 0 to 29 mm). ETO fragment migration of >1 cm occurred in 7% (37) of the 501 hips that had radiographic analysis. Nine hips (2%) had nonunion of the ETO. Intraoperative fracture of the ETO diaphyseal fragment occurred in 22 hips (4%), postoperative fracture of the ETO diaphyseal fragment occurred in 3 hips (0.5%), and postoperative fracture of the greater trochanter occurred in 41 hips (7%). Survivorship at 10 years free of revision for aseptic femoral loosening, free of femoral or acetabular component removal or revision for any reason, and free of reoperation for any reason was 97%, 91%, and 82%, respectively. Conclusions: This large series of ETOs shows that the union rate is high and clinically important trochanteric migration is infrequent. The most common complications are fracture of the osteotomy fragment intraoperatively or postoperatively. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Mary Ella Mascia Pierpont: Geneticist, scientist, mentor, friend (1945–2020)
Pierpont, Elizabeth I. , Berry, Susan A. , Lin, Angela E. , Lohr, Jamie L. , Schimmenti, Lisa A. , Dobyns, William B. , Schimmenti, Lisa A

Mayo Clinic

American Journal of Medical Genetics Part A | November 26, 2020 | Volume: 185 | Issue: 2 | Pages: 319-323

10.1002/ajmg.a.61963 | PMID 33241662 Get It

A Potential Theragnostic Regulatory Axis for Arthrofibrosis Involving Adiponectin (ADIPOQ) Receptor 1 and 2 (ADIPOR1 and ADIPOR2), TGFβ1, and Smooth Muscle α-Actin (ACTA2)
Bayram, Banu , Owen, Aaron R. , Dudakovic, Amel , Dagneaux, Louis , Turner, Travis W., Bettencourt, Jacob W. , Limberg, Afton K. , Tibbo, Meagan E. , Berry, Daniel J., Kocher, Jean‐Pierre , Wijnen, André J. van , Berry, Daniel J. , Sanchez-Sotelo, Joaquin, Kocher, Jean-Pierre A , van Wijnen, Andre J , Berry, Daniel J , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Berry, Daniel J., Abdel, Matthew P.

Mayo Clinic

Journal of Clinical Medicine | November 17, 2020 | Volume: 9 | Issue: 11 | Pages: 3690

10.3390/jcm9113690 | PMID 33213041 Get It

(1) Background: Arthrofibrosis is a common cause of patient debility and dissatisfaction after total knee arthroplasty (TKA). The diversity of molecular pathways involved in arthrofibrosis disease progression suggest that effective treatments for arthrofibrosis may require a multimodal approach to counter the complex cellular mechanisms that direct disease pathogenesis. In this study, we leveraged RNA-seq data to define genes that are suppressed in arthrofibrosis patients and identified adiponectin (ADIPOQ) as a potential candidate. We hypothesized that signaling pathways activated by ADIPOQ and the cognate receptors ADIPOR1 and ADIPOR2 may prevent fibrosis-related events that contribute to arthrofibrosis. (2) Methods: Therefore, ADIPOR1 and ADIPOR2 were analyzed in a TGFβ1 inducible cell model for human myofibroblastogenesis by both loss- and gain-of-function experiments. (3) Results: Treatment with AdipoRon, which is a small molecule agonist of ADIPOR1 and ADIPOR2, decreased expression of collagens (COL1A1, COL3A1, and COL6A1) and the myofibroblast marker smooth muscle α-actin (ACTA2) at both mRNA and protein levels in basal and TGFβ1-induced cells. (4) Conclusions: Thus, ADIPOR1 and ADIPOR2 represent potential drug targets that may attenuate the pathogenesis of arthrofibrosis by suppressing TGFβ-dependent induction of myofibroblasts. These findings also suggest that AdipoRon therapy may reduce the development of arthrofibrosis by mediating anti-fibrotic effects in joint capsular tissues.
Plasma neurofilament light predicts mortality in patients with stroke
Gendron, Tania F. , Badi, Mohammed K. , Jansen‐West, Karen , Vilanilam, George K. , Burch, Alexander R. , Walton, Ronald L., Ross, Owen A. , Brott, Thomas G. , Miller, Timothy M. , Nicholson, Katharine, Oskarsson, Björn , Falcone, Guido J. , Cucchiara, Brett , Petrucelli, Leonard , Jansen-West, Karen R , Vilanilam, George , Johnson, Patrick W. , Burch, Alexander R , Ross, Owen A , Miller, Timothy M , Wszolek, Z.K. , Oskarsson, Björn , Sheth, Kevin N , Sansing, Lauren H , Falcone, Guido J , Cucchiara, Brett L , Meschia, James F , Petrucelli, Leonard , Badi, Mohammed , Gendron, Tania F , Heckman, Michael G. , Berry, James D. , Wszołek, Zbigniew K. , Sheth, Kevin N. , Meschia, James F.

Mayo Clinic

Science Translational Medicine | November 12, 2020 | Volume: 12 | Issue: 569 | Pages: No page available

10.1126/scitranslmed.aay1913 | PMID 33177179 Get It

Plasma neurofilament light is a reliable, uniform marker to estimate neuroaxonal injury and forecast all-cause mortality across major stroke types.
S2894 Jaundice, Elevated Beta-Human Chorionic Gonadotropin, and Female Gender: Duodenal Choriocarcinoma, Not Pregnancy
Berry, Nick A., Sobrado, Javier, Mohan, Karthik , Berry, Bruce, Berry, Andrew C. , Berry, Bruce B.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S1517-S1517

10.14309/01.ajg.0000713624.51210.53 Get It